Sanford C. Bernstein Increases DexCom (NASDAQ:DXCM) Price Target to $86.00

DexCom (NASDAQ:DXCM) had its price objective upped by Sanford C. Bernstein from $82.00 to $86.00 in a research note published on Friday morning, Benzinga reports. Sanford C. Bernstein currently has an outperform rating on the medical device company’s stock.

Other analysts have also issued reports about the company. Canaccord Genuity Group reiterated a “buy” rating and set a $145.00 price objective on shares of DexCom in a report on Tuesday, July 23rd. Robert W. Baird increased their price objective on DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a report on Monday, August 5th. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a report on Saturday, October 12th. Stifel Nicolaus increased their price objective on DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, August 23rd. Finally, JPMorgan Chase & Co. raised their target price on DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a report on Friday. Six equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $104.59.

DexCom Price Performance

NASDAQ DXCM opened at $73.44 on Friday. The firm has a market capitalization of $29.21 billion, a PE ratio of 47.38, a P/E/G ratio of 2.26 and a beta of 1.18. DexCom has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48. The company’s 50 day simple moving average is $70.11 and its 200 day simple moving average is $97.95.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The firm’s revenue for the quarter was up 15.3% compared to the same quarter last year. During the same period last year, the firm posted $0.34 earnings per share. As a group, equities research analysts forecast that DexCom will post 1.69 EPS for the current fiscal year.

Insider Activity

In other news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Michael Jon Brown sold 652 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total value of $45,346.60. Following the completion of the sale, the executive vice president now directly owns 66,249 shares in the company, valued at approximately $4,607,617.95. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,824 shares of company stock valued at $126,390. 0.30% of the stock is owned by insiders.

Institutional Investors Weigh In On DexCom

Institutional investors have recently added to or reduced their stakes in the company. Taylor Frigon Capital Management LLC grew its position in DexCom by 51.6% during the third quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock worth $2,182,000 after buying an additional 11,075 shares in the last quarter. Waters Parkerson & CO. LLC grew its position in DexCom by 4.2% during the second quarter. Waters Parkerson & CO. LLC now owns 272,641 shares of the medical device company’s stock worth $30,912,000 after buying an additional 10,892 shares in the last quarter. Legal & General Group Plc grew its position in DexCom by 1.7% during the second quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock worth $339,352,000 after buying an additional 49,076 shares in the last quarter. Factory Mutual Insurance Co. grew its position in DexCom by 136.1% during the third quarter. Factory Mutual Insurance Co. now owns 404,230 shares of the medical device company’s stock worth $27,100,000 after buying an additional 233,000 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund grew its position in DexCom by 533.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 36,510 shares of the medical device company’s stock worth $4,140,000 after buying an additional 30,743 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.